Twinrab^™ is the 1st and only approved cocktail for Rabies virus neutralization

Twinrab^™ is a novel monoclonal antibody (mAb) cocktail targeting non-overlapping epitopes on the rabies virus glycoprotein. It is a passive immunization therapy for the post exposure prophylaxis (PEP) of rabies, particularly for Category III exposures, given in combination with rabies vaccination. Twinrab™ is intended as an alternative to plasma derived human or equine rabies immunoglobulins (HRIG/ERIG), addressing limitations related to cost, supply constraints, batch variability, and biosafety risks.

Twinrab^™ comprises two murine monoclonal antibodies with complementary and defined specificity, providing broad neutralization coverage against phylogenetically diverse rabies virus strains. The efficacy and neutralization breadth of Twinrab™ have been evaluated using WHO aligned protocols, including in vivo challenge studies with divergent rabies virus strains.

Twinrab^™ is the world’s first and only monoclonal antibody cocktail approved for use in post-exposure prophylaxis upon animal bite. It received marketing approval from the Drug Controller General of India (DCGI) in 2019 and is developed in alignment with the World Health Organization’s recommendations to replace plasma derived rabies immunoglobulins with mAb based products. Twinrab™ supports the global objective of improving access to safe, effective, and scalable life saving rabies PEP, particularly in low and middle income countries with a high disease burden.